All In Biotech

Drug Trial Radar · NCT07801326

A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese Participants

A Randomized, Open-Label Study to Evaluate the Effects of Different Dosing Conditions and Post-Dose Meal Timing on the Pharmacokinetics of MWN109 Tablets in Chinese Adult Participants

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

162

Actual

Start

May 24, 2026

Primary completion

Aug 10, 2026

Study completion Aug 10, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multiple-dose study to evaluate the effects of different volumes of administration water, post-dose fasting duration, and high-fat diet on the pharmacokinetics of the 15 mg dose of MWN109 tablets in adult Chinese participants, as well as to assess its safety, tolerability, and immunogenicity. The study consists of two parts. Part 1 is an administration condition study, which includes 6 groups stratified by post-dose fasting duration and administration water volume. Part 2 is a food-effect study, comprising 3 groups stratified by dietary conditions.. A total of 162 participants are planned to be enrolled. The primary endpoint is pharmacokinetics (PK). PK parameters include Cmax, Cmin, AUC0-t, AUC0-∞, Tmax, and t1/2. Secondary endpoints include safety (adverse events \[AEs\] and serious adverse events \[SAEs\]) and immunogenicity (anti-drug antibodies \[ADAs\]).

Conditions

  • Type 2 Diabetes Mellitus (T2DM)
  • Overweight , Obesity

Interventions

  • MWN109 TabletsDrug

    administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Concentration (Cmax)Time frame: From Day 1 to Day 29
  2. Minimum Concentration (Cmin)Time frame: From Day 1 to Day 29
  3. Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t)Time frame: From Day 1 to Day 29
  4. Area Under the Curve From Time 0 to Infinity (AUC0-inf)Time frame: From Day 1 to Day 29
  5. Time to Reach Maximum Concentration (Tmax)Time frame: From Day 1 to Day 29
  6. Elimination Half-Life (t1/2)Time frame: From Day 1 to Day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Yunnan University of Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine)

    Kunming, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.